异动解读|CRISPR Therapeutics AG盘中上涨5.28%,CTX310与zugo-cel临床进展持续发酵

行情直击
Yesterday

11月18日,CRISPR Therapeutics AG盘中上涨5.28%,报42.26美元/股,成交额905.65万美元。

消息面上,公司近期两项临床更新持续受到市场关注:CTX310在1b期试验中实现ANGPTL3平均下降65%、甘油三酯下降63%;自身免疫项目zugo-cel在难治性风湿免疫疾病早期研究中亦披露积极结果。

此外,券商日前重申买入评级并给出80美元目标价,叠加Casgevy商业化使用增长,强化了市场对其基因编辑平台与管线兑现能力的关注。不过,公司此前季度EPS为-1.15美元,低于预期,显示股价反弹仍建立在临床进展驱动之上。

(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10